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ABSTRACT: Fusion-tag afﬁnity chromatography is a key technique
in recombinant protein puriﬁcation. Current methods for protein
recovery from mammalian cells are hampered by the need for feed
stream clariﬁcation. We have developed a method for direct capture
using immobilized metal afﬁnity chromatography (IMAC) of
hexahistidine (His6) tagged proteins from unclariﬁed mammalian
cell feed streams. The process employs radial ﬂow chromatography
with 300–500mm diameter agarose resin beads that allow free
passage of cells but capture His-tagged proteins from the feed stream;
circumventing expensive and cumbersome centrifugation and/or
ﬁltration steps. The method is exempliﬁed by Chinese Hamster
Ovary (CHO) cell expression and subsequent recovery of
recombinant His-tagged carcinoembryonic antigen (CEA); a heavily
glycosylated and clinically relevant protein. Despite operating at a
high NaCl concentration necessary for IMAC binding, cells remained
over 96% viable after passage through the column with host cell
proteases and DNA detected at 8 U/mL and 2 ng/mL in column
ﬂow-through, respectively. Recovery of His-tagged CEA from
unclariﬁed feed yielded 71% product recovery. This work provides
a basis for direct primary capture of fully glycosylated recombinant
proteins from unclariﬁed mammalian cell feed streams.
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Introduction
Expression of recombinant proteins in yeasts, bacteria, and
mammalian cells is now routine practice at industrial scale.
Although microbial expression systems are used to produce the
majority of industrial recombinant proteins, those requiring
glycosylation for correct structure and function are preferentially
expressed in mammalian host systems (Dean and Reddy, 2013; Lai
et al., 2013; Wurm, 2004; Zhu, 2011). The glycosylation proﬁle of
proteins from microbial cells differs from that of mammalian cells
(Demain and Vaishnav, 2009). Incorrectly glycosylated proteins
from microbial sources can be non-functional (Buck et al., 2013)
and even induce patient immune responses (Jacobs et al., 2008;
Jefferis, 2012).
A disadvantage of mammalian cell expression is the high cost of
goods/gram of product (COG/g) when compared to microbial
expression. However, in the past a substantial percentage of these
costs derived from fermentation, whereas recently production costs
have become more heavily weighted toward downstream processing
(Gonzalez et al., 2003). This is largely due to improvements in speciﬁc
productivity, better feeding strategies, and protein engineering;
combining to produce cell densities in excess of 1 107 cells/mL and
yields of 8 g/L (Farid, 2007; Hacker et al., 2009). These advances have
in turn created new challenges for downstreamprocessing, leading to
a focus on developing high capacity methods for the primary capture
of protein from high cell density feeds.
Current methods for primary capture of recombinant protein
necessitate solid–liquid separation to remove cells and debris,
followed by chromatographic capture steps based on ion exchange
or afﬁnity. Typically, solid–liquid separation consists of centrifu-
gation and ﬁltration. These techniques can account for up to 25%
COG/g when factors such as capital cost and energy consumption
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are included (Marichal-Gallardo and Alvarez, 2012). Primary
processing of high cell density feed streams requires particular
consideration to avoid cell stresses and shearing that could result in
protein aggregation and cell lysis (Hutchinson et al., 2006; Kiese
et al., 2008). The latter affects the quantity and quality of product
through the release of host cell proteins (HCP), proteases, and DNA
(Sandberg et al., 2006). Attractive options for primary recovery
include use of resins in the form of large diameter beads that create
a highly porous bed enabling simultaneous protein capture and
concentration whilst allowing cells to pass through. Such large bead
diameter chromatography resins are made from agarose beads
typically between 300mm and 500mm in diameter that can be
combined with radial ﬂow chromatography (RFC). By contrast to
axial ﬂow, RFC consists of two concentric cylindrical porous frits
holding a stationary phase between them. In RFC, feed ﬂows from
the outer to the inner surface across the radius of the column
(Fig. 1A) providing a minimal pressure drop. Improved elution peak
resolution due to the trapezoidal column geometry and greater
operational ﬂow rates are reported as advantages (Besselink et al.,
2013). RFC columns can be packed with many resins depending on
frit design, including ion exchange (IEX), immobilized metal
afﬁnity chromatography (IMAC) or protein A/G and are easily
scalable.
Recombinant protein puriﬁcation has long relied on the use of
engineered afﬁnity tags, which can be used to facilitate capture, in
addition to improving expression and solubility of proteins (Young
et al., 2012). The polyhistidine repeat tag, however, remains the
major workhorse for afﬁnity puriﬁcation due to the simplicity of
amino or carboxy terminal fusion to proteins that lack a natural
puriﬁcation tag (Terpe, 2003). Concerns have been raised about the
potential of therapeutically redundant puriﬁcation tags to affect in
vivo half life, therapuetic function of proteins or be implicated in
immunogenicity. Although tags can be removed after puriﬁcation
(Waugh, 2011), His-tagged proteins have been used in a number of
clinical products without adverse effects (Tolner et al., 2013,
Table 37.1). Data present in GenBank (http://www.ncbi.nlm.nih.
gov/genbank) also reveal a variety of human proteins containing
stretches of six or more consecutive histidines. The occurrence of
these sequences in human proteins makes this sequence an unlikely
candidate to be involved in immunogenicity.
IMAC offers an inexpensive, robust, and versatile approach to
protein capture chromatography (Shukla et al., 2001). In addition to
the recovery of tagged proteins, IMAC capture of recombinant
proteins with naturally occurring histidine rich regions has also
been demonstrated, including antibodies and antibody fragments
(Cheung et al., 2012; Todorova-Balvay et al., 2004). Hexahistidine
(His) tagged proteins have been IMAC captured without the need
for feed stream clariﬁcation from microbial hosts previously
(Tolner, 2006; Willoughby, 2004), however, direct capture from
mammalian cells is more challenging due to the increased
sensitivity of cells to shear and also the high salt concentration
required for IMAC binding.
Here, we report the development of a process using RFC packed
with a large diameter resin to obtain an integrated primary capture
step for unclariﬁed CHO cell fermentation feed streams. The method
was developed using suspension-adapted CHO cells grown in shake
ﬂask culture and puriﬁed on a micro-RFC column with 6 cm bed
height loaded with Sterogene CellThru Bigbead IMAC resin. The
process was then scaled up to a 1 L feed whilst chromatography bed
height was maintained. We based the study upon recovery of CEA, a
clinically relevant glycoprotein used in many diagnostic and
therapeutic applications (Francis et al., 2002; Girgis et al., 2011;
Graff et al., 2004; Kaushal et al., 2008; Prager et al., 2014). CEA has
previously proved difﬁcult tomanufacture as a complete glycoprotein
in recombinant form and attempts to express it in yeasts have yielded
only truncated forms (Hellwig, 1999; Sainz-Pastor, 2006; Tolner,
2013), hence the demand has been met by recovery from ascetic
ﬂuids (Hammarstr€om, 1999; Sigma–Aldrich, St. Louis, MO). CEA is
50–60% glycosylated by weight making microbial expression
unsuitable (Paxton et al., 1987). The study forms the basis of a
primary capture step applicable to the recovery of many recombinant
proteins from unclariﬁed mammalian cell feed streams.
Figure 1. Radial flow chromatography methods. A: Axial and radial flow chromatography. Frits are located at the outer and inner circumferences of the radial column. Bed
height (H), flow direction (F). B: Process flow diagram of integrated radial flow chromatography control.
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Materials and Methods
Cell Lines and Maintenance
Suspension and serum free adapted Chinese Hamster Ovary cells
(CHO-S) (Life Technologies, Paisley, UK) or CHO-S expressing
His-tagged CEA (CHO-CEA) were seeded at a density of
0.3 million viable cells (MVC)/mL in 300mL of a 1:1 (v/v)
mix of CD-CHO (Life Technologies) and EX-CELL CD-CHO 3
(Sigma–Aldrich) in 1 L Erlenmeyer ﬂasks (Corning Limited,
Union City, CA) with 0.22mm vented caps to a maximum cell
density of 3 106 cells/mL. All incubation conditions were
125 rpm, 8% CO2, and 37C.
Cell Counting, Viability, and Size Distribution
A Vi-CELL XR automated cell counter (Beckman Coulter, High
Wycombe, UK) was used to determine cell density and viability via
the Trypan blue exclusion method. Vi-CELL parameters were min/
max size 6–50mm and 50 counts. Particle size distribution was
analyzed using the CASY Cell Counter Analyzer System (Roche,
Basal, Sweden) with analyses parameters set to min/max 3–40mm.
Cell culture was diluted in phosphate buffered saline (PBS) where
appropriate to ensure accuracy in cell counting and particle
distribution analyses.
Media Bioprofiling
Media composition and cell culture metabolites were analyzed by
ion selective electrode potentiometry, amperometry, and enzymatic
reaction-dependent biosensors in 1mL aliquots immediately after
sample removal (BioProﬁle 400, Nova Biomedical, Inc., Waltham,
MA).
Radial Flow Chromatography Operation
A scale down RFC column with bed volume of 5mL and height of
6 cmwas used with either 40mm or 200mmpore size frits (Proxcys,
Nieuw-Amsterdam, Netherlands) (Fig. 1A). The column was
packed with iminodiacetic acid (IDA) Chelating CellthruTM BigBead
agarose resin (Sterogene, Carlsbad, CA) as per the manufacturers
instructions. Column conditioning was performed to remove air
bubbles with 6 column volumes (CV) PBS (pH 7.2). The resin was
charged with 5CV 100mM nickel sulphate and equilibrated with
0.5M NaCl/ 0.5 PBS/ 10mM imidazole. An operational ﬂow rate
of 1 CV/min was used for column loading, achieved using a
peristaltic pump (New MBR, Zurich, Switzerland). Whilst frit pore
sizes of both 200mm and 40mmwere studied, the 200mm pore frit
was used routinely. Non-speciﬁcally bound proteins were removed
via wash buffer (40mM imidazole/ 0.5X PBS/ 0.5M NaCl) before
elution with 200mM imidazole/0.5X PBS/ 0.5 M NaCl. The column
was stripped and regenerated after each use using 50mMNA-EDTA
and stored in 20% (v/v) ethanol.
Feed Clarification
Where feed was clariﬁed, centrifugation at 500g for 20min in an
Avanti J-26 XPI (Beckman Coulter, Woerdan, The Netherlands) was
used to remove solids before ﬁltration through a 500mL 0.22mm
Stericup ﬁlter unit (Corning Limited).
Bioreactor Fermentation
A single-use pneumatic bioreactor from PBS Biotech, Inc (CA) with a
working volume of 3 L was used for scaled up cell culture. Sterile
polycarbonate gamma-irradiated SUT 3 Lunits (PBSBiotech Inc, CA)
were seeded with CHO-CEA cells at a density of 0.3 106 cells/mL.
Reactor conditions were set at 37C with 25 RPM pneumatic vertical
wheel agitation, pH 7.2 and >30% DO2 maintained via PID control
(Kim et al., 2013). Cells were maintained in a fed-batch mode of
operation with 3% (v/v) EfﬁcientFeed B (Life Technologies) daily
from Day 4. Once cells reached the end of the exponential growth
phase temperature and agitation were reduced to 35C and 20 RPM,
respectively (Nam et al., 2008).
Column-Reactor Integration and Harvest
In-line integration of RFC was achieved via welding the column
tubing directly to the reactor harvest line using Masterﬂex C-FLEX
tubing (Cole-Palmer, London, UK) with a sterile tube welder (GE
Healthcare, Buckinghamshire, UK). Valve and pump operation was
used to control ﬂow from the reactor (Valves 1 and 3 open), followed
by wash, elution and regeneration buffers (Valves 2 and either 3 or 4
open) (Fig. 1B). Cells were buffered to IMAC binding conditions by
addition of 4x concentrated IMAC buffer to the reactor prior to
passage directly through the column in 3 1 L batches. The column
was eluted and regenerated between batches as described above.
Protease Activity Quantification
Protease activity in the supernatant and column ﬂow-through was
determined using the ﬂuorescence resonance energy transfer
(FRET) protease assay (Life Technologies) according to the
manufactures instructions. Brieﬂy, 100mL of casein labeled stock
solution (10mg/mL) or assay buffer as blank was added to eachwell
of a black 96-well plate. Supernatant (50mL) was added and
incubated for 20–30min at room temperature before addition of
50mLTNBSA solution and a further incubation of 20min at room
temperature. The assay plate was read in a Varioskan Flash plate
reader (Life Technologies) in ﬂuorescence mode at 485/538 nm.
Activity was quantiﬁed against a standard curve of trypsin with
known proteolytic activity, 15,525 U/mg (1 U deﬁned as a change in
absorbance at 253 nm of 0.001/min at 25C, pH 7.6 in a reaction
volume of 3.2 mL of Na-Benzoyl-L-Arginine Ethyl Ester Solution
(BAEE) (Papaioannou and Liener, 1968).
Real-Time qPCR
Real time PCR (adapted from Nissom, 2007) was performed using a
Realplex4 Mastercycler EPgradient S (Eppendorf, Stevenage, UK)
using the following conditions: initial heat denaturation at 50C for
2min, 95C for 10min, followed by 40 cycles each of 95C for 15 s
and 60C for 1min. Primers directed against genomic DNA isolated
from Critcetulus griseus (CHO) were synthesized by IDT (Integrated
DNA Technologies, Glasgow, UK). Primer sequences were: Sense
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50ACAGGTTTCTGCTTCTGGCT and Anti-sense 50CATCAGCTGA
CTGGTTCACA. The reaction mix contained 3mL of sample in a
25mL reaction mixture of ITAQ SYBR with a ﬁnal concentration of
5 nM of each primer.
Enzyme Linked Immunosorbant Assay (ELISA)
CEA was quantiﬁed using a double antibody sandwich ELISA
method. A 96-well plate (Life Technologies) was coated with
10mg/mL polyclonal rabbit anti-CEA (UCL Cancer Institute,
London). After washing with PBS twice, wells were blocked with
200mL of 5% (w/v) skimmed milk in PBS. Plates were washed as
before and samples were added along with a serial dilution of His-
tagged CEA (R&D, Abingdon, UK) to form a standard curve. After
washing, 1mg/mL murine anti-CEAwas added for 1 h and detected
using anti-mouse-horseradish peroxidase (HRP) conjugate (R&D,
Abingdon, UK) diluted 1:4,000 in phosphate buffered saline (PBS),
using 0.5 mg/mL o-phenylenediamine dihydrochloride (Sigma–
Aldrich) in phosphocitrate buffer for development. Color was
analyzed by absorbance at 490 nm in a Varioskan Flash platereader
(Life Technologies). All incubations were carried out at room
temperature.
Model His-Tagged Protein Recovery
A His-tagged ScFv (SM3E) (Graff et al., 2004) was expressed and
puriﬁed from Pichia pastoris as previously described (Tolner et al.,
2006) and used as the test protein for recovery from cell culture
media. Ultraviolet light absorbance and conductivity were analyzed
by linking the RFC to an Akta Prime Plus (GE Healthcare). Eluted
fractions were resolved by 10% (v/v) sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE), stained for 1 h
with Coomassie Brilliant Blue (Sigma–Aldrich) and destained until
clear using a mixture of 10% (v/v) glacial acetic acid, 30% (v/v)
methanol, and 60% (v/v) double distilled water (ddH2O).
Western Blotting
Puriﬁed His-tagged CEAwas quantiﬁed via ELISA assay and diluted
to 1mg/mL before being resolved by SDS–PAGE as above and
transferred to polyvinylidene diﬂuoride (PVDF) membranes
(BioRad, Hercules, CA). His-tagged CEA (R&D) was used as
positive control. Membranes were blocked with 5% (w/v) skimmed
milk powder in 0.1% (v/v) PBS and probed with murine anti-His tag
(Qiagen, Limburg, Netherlands) or an anti-CEA antibody (Pedley
et al., 1987). Bound antibodies were detected with HRP-linked
secondary anti-mouse-HRP conjugated antibody (R&D, Abingdon,
UK) and developed using Luminata ClassicoWestern HRP substrate
(Millipore, Darmstadt, Germany).
Design of Experiments
A central composite design (CCD) was used for optimization of
buffer conditions for His-tagged CEA Ni-IMAC binding. Three
variables were investigated with parameters based on standard
IMAC binding buffers; (A) pH, (B) NaCl concentration (mM), and
(C) imidazole concentration (mM). Clariﬁed supernatant (100mL)
containing His-tagged CEA was adjusted to the appropriate buffer
composition and randomized using the design matrix (Table I)
prior to capture using a 5mL HisTrap column (GE Healthcare). CEA
yield was assessed via ELISA and process interactions were
analyzed using Design-Expert 8 (Stat-Ease, Inc., MN).
Results
CHO Cell Passage Through Radial Flow Column
The average diameter of CHO cells (14.02–15.21mm; Han et al.,
2006) was used to select frit pore sizes for the column. Frits were
sized so as to enable CHO cell passage without allowing the 300mm
IMAC beads to escape the column. Pores of 40mm and 200mm
were chosen for pilot experiments using shake ﬂask feed stocks of
CHO-S at a density of 1 106 cells/mL (97.4% viable). Results from
these experiments showed that the cell density of the feedstream
passed through the 40mm pore size frit dropped by 35% and the
remaining cells had a reduced viability (19.38% 2.3%). By
contrast, cells remained viable (97% 2.2%) when the feed was
passed through a 200mm pore size frit. All further experiments
were, therefore, carried out using the 200mm pore frit.
The effect of increased cell densityon cell passage through the column
was analyzed using shake-ﬂask feeds with 0.5–8.5 106 cells/mL.
Greater than 98% of cells remained viable in the ﬂow-through from feed
streams containing >1 106 cells/mL (Fig. 2A). This data was
conﬁrmed via analysis of cell lysis indicators including host cell DNA
(hDNA) and proteolytic activity. The same markers showed no
signiﬁcant difference between pre/post column samples (P> 0.05)
(Fig. 2B and C).
Cell integrity was assayed via examination of the particle size
distribution of feed streams pre and post column. Counts of
particulate matter from cell lysis and protein aggregation
(<6.7mm) and larger particles such as cell aggregates
(>22mm) increased in proportion with cell density. Differences
in the size distribution of samples from pre-column and ﬂow-
through samples were low in feed streams containing 0.5, 1, 2, or
8.5 106 cells/mL, which is consistent with previous results.
Washing of the column resulted in effective DNA clearance (zero
detection via qPCR), a decrease in proteolytic activity to <2 U/mL
and a low particulate count in all conditions (Fig. 2B, C and Fig. 3).
These data veriﬁed that CHO cells survived passage through the
column without signiﬁcant detrimental effects.
Table I. Design Matrix for Optimization of IMAC Binding Buffer From
Unclarified CHO Feed
pH NaCl (nM) Imidazole (nM)
8.5 500 10
8.5 500 30
7.5 500 10
7.5 111 10
8.5 111 30
8 305 20
7.5 111 30
8.5 111 10
8 305 20
7.5 500 30
4 Biotechnology and Bioengineering, Vol. 9999, No. xxx, 2015
IMAC Capture of Model His-Tagged Protein From
Fermentation Media
Recovery of His-tagged proteins is dependent on the composition of
media from which it is puriﬁed; accordingly, media is usually
buffered to favor IMAC binding conditions prior to puriﬁcation. We
simulated IMAC capture at the end of CHO-S fermentation using
media from a 12-day-old non-transfected shake ﬂask culture that
had been clariﬁed and spiked with 1mg/mL His-tagged ScFv (His-
SM3E). Protein recovery using the radial ﬂow bed was analyzed
Figure 2. Analysis of unclarified feed streams containing different densities of CHO cells before and after passage through a scale down RFC with large bead resin (n¼ 3).
A: Percentage cell viability of unclarified feed stream in pre-column, flow through and washing conditions. B: qPCR quantification of host cell DNA in pre-column and flow through
conditions. C: Quantification of supernatant protease activity in unclarified feed stream and maximum cell lyses samples.
Figure 3. Particle size distribution of crude feed streams applied to a scale down radial-flow column packed with large bead resin. Feed stream cell density; (A) media only,
(B) 0.5 106 cells/mL, (C) 1 106 cells/mL, (D) 2 106 cells/mL, (E) 3 106 cells/mL, (F) 8.5 106 cells/mL. Blue indicates pre-column sample, red flow through, and green PBS wash.
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using both un-buffered and buffered media conditions. Un-buffered
media received no addition prior to chromatography whilst buffered
media was adjusted to 150mM NaCl, pH >7.5 with 20mM
imidazole. Total product recovery was improved in buffered media,
83% versus 61%, as determined by absorbance at 280 nm (data not
shown). UV absorbance and SDS–PAGE resolution of protein
captured from buffered media showed that the main protein
fraction was eluted in CV3 and CV4. There was no visible protein
band in the column ﬂow-through suggesting adequate binding to
the IMAC matrix (Fig. 4). The model protein was successfully
recovered from media conditioned to simulate typical harvest
conditions, showing that His-tag recovery was feasible using the
combination of large bead resin and scaled down radial ﬂow
column.
Buffer Optimization for His-Tagged CEA Recovery
Having established that His-tagged proteins could be recovered
from buffered media, we focused on recovery of the target protein
after expression by CHO-CEA cells. Buffer optimization was
performed in order to achieve maximum recovery of the target
protein from clariﬁed shake ﬂask supernatant. DesignExpert8
(Shukla et al., 2001) was used to determine the necessary
experimental parameters for optimizing buffer composition. A
central composite, two-level, three-factorial design was used to
investigate the effects of pH, NaCl, and imidazole concentration on
product recovery. One signiﬁcant factor interaction was found
between pH and NaCl concentration (P< 0.05) (Fig. 5A and B).
Percentage recovery ranged between 36–73%. Reducing NaCl
concentration at high pH and increasing it at lower pH showed
equally improved recovery of CEA (Fig. 5C and D). The lower pH of
7.5 was selected for further experiments to reduce cell stress whilst
imidazole was maintained at a concentration of 20mM after no
effect was found on CEA yield. However puriﬁcation at pH 7.5
meant that a high concentration of NaCl was required (500mM)
with potential negative effects on cell integrity.
Cell Survival in Optimized IMAC Buffer Conditions
We next investigated the effects of high salt concentration and IMAC
buffering on feed characteristics and cell survival. Viability was
reduced by2% and 5%, respectively, over 1 h in shake ﬂasks with
Figure 4. FPLC and SDS–PAGE separation of eluted fractions of a model His-tagged single-chain variable fragment from conditioned media buffered to IMAC binding
conditions. Red numbers indicate 1mL fraction collection.
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200mM and 500mM NaCl, whilst feeds exposed to 750mM and
1,000mMNaCl reduced by as much as 34% (Fig. 6A). Consequently
binding buffer composed of 500mM NaCl, 20mM imidazole, and
a pH of 7.5 was selected for use in further experiments. CHO-S cells
in IMAC buffered media were passed through the column to
determine the impact on feed characteristics. Percentage viability in
the ﬂow-through remained >98% whilst host cell contaminants
remained low (protease activity 8 U/mL and 2 ng/mL hDNA)
(Fig. 6B and C). Particle size distribution corroborated these results
showing no signiﬁcant difference (P> 0.05) between pre-column
and ﬂow-through samples (Fig. 6D) as seen previously with passage
of CHO-S cells through the column. Our results indicated that the
optimized IMAC buffer did not substantially affect cell character-
istics, nor increase protease levels in the feed or eluted fractions.
Comparing Recovery of His-Tagged CEA From Unclarified
and Clarified Shake Flask Feed Streams
Once the optimum buffer composition had been chosen, we
investigated the effect of media clariﬁcation on His-tagged CEA
recovery in the radial ﬂow column and compared this with recovery
from a commercial axial ﬂow column (HisTrap). CHO cells
expressing His-tagged CEAwere cultivated in fed-batch shake ﬂask
conditions for 12 days (Fig. 7A). Feed was buffered and applied to
the column either clariﬁed or unclariﬁed. Cells from the unclariﬁed
feed remained 97% viable in column ﬂow-through with low
contamination levels of7.5 U/mL protease activity and>2 ng/mL
hDNA (Fig. 7B and C) and a particle size distribution that was
indistinguishable from results shown previously (Figs. 3 and 6D).
No difference in proteolytic activity was observed between
unclariﬁed and clariﬁed feeds (Fig. 7B), however, the hDNA
quantity decreased in both clariﬁed conditions, (1.95 ng/mL from
radial ﬂow and 0.78 ng/mL from HisTrap columns compared to
2.77 ng/mL fromunclariﬁed feed). Protein recovery was higher from
clariﬁed media than from unclariﬁed media (Fig. 7C), with the
standard packed-bed HisTrap column achieving 89% recovery,
the radial ﬂow 78% and unclariﬁed feed 71% (Fig. 7D).
Integrated His-Tagged CEA Recovery From Bioreactor
Fermentation
Integration of the column and bioreactor was carried out using fed-
batch fermentation. The bioreactor feed had an increased cell
density and product titer compared to shake ﬂask growth
(11.8 106 cells/mL and 7.2mg/mL CEA) (Fig. 8A and B). Feed
was harvested via passage directly through the column in 1 L
batches with subsequent regeneration to ensure consistency (see
Methods Section). Cell viability and feed stream characteristics
Figure 5. Design of experiments based optimization of buffer composition for IMAC capture of His-tagged CEA. A: Pareto Chart indicates significant factor interactions above 1
value limit (black line). Blue indicates negative effects, orange positive effects and hollow significant effects (Factor labels; a¼ pH, b¼NaCl, c¼ imidazole). B: Factor interaction of
NaCl and pH (Red¼ 500mM NaCl, Black¼ no NaCl addition). C: 2D, and (D) 3D surface response curve of His-tagged CEA capture.
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were not signiﬁcantly different to previous experiments. Average
product recovery was 69% (6%) in repeated batch puriﬁcations
giving a ﬁnal pooled sample yield of 14.6 mg as determined
by ELISA. Fractions from individual puriﬁcations were diluted to
1mg/mL for Western blotting and were visualized using both anti-
CEA and anti-His antibodies (Fig. 8C and D). There was no visible
difference between subsequent puriﬁcations. Bands for CEA, but
not His-tag, were identiﬁed in ﬂow-through from the column
indicating that His-tag recovery was efﬁcient and the apparent
lower yield compared to equivalent shake ﬂask material was due to
untagged or degraded CEA passing through the column.
Discussion
Primary capture of recombinant proteins frommammalian cells is a
lengthy procedure with potential for gains in efﬁciency, spurred by
the increasing focus on manufacturing (Farid, 2007), which is
currently estimated at 50–80% of total process costs (Levy et al.,
2014). We have addressed this by developing an integrated primary
capture step for recovery of secreted, His-tagged recombinant
proteins from unclariﬁed mammalian cell feeds using RFC operated
with large diameter resins. As yield is a function of the number of
processes (Farid, 2011), it is advantageous to remove process steps
where possible. Process efﬁciency can be achieved by improved
integration of steps immediately following fermentation (Warikoo
et al., 2012), with the added beneﬁt of reducing process volumes,
CAPEX, operator costs, and consumables.
In this study IMAC puriﬁcation was utilized for the recovery of a
complex glycoprotein from CHO cells. Demand for CEA has been
met previously by recovery from ascetic ﬂuids (Hammarstr€om,
1999, Sigma–Aldrich). Attempts to express it in the yeast P. pastoris
have achieved expression of only truncated forms of the protein
(Hellwig et al., 1999; Sainz-Pastor et al., 2006; Tolner et al., 2013).
Consequently CEA, like many other recombinant proteins, requires
expression in mammalian or glyco-engineered insect cells to ensure
correct glycosylation for structure and function. CEA is currently
available commercially from recombinant or human sources and is
widely used in diagnostic applications; however, it remains an
expensive protein with inconsistent glycosylation proﬁles. As with
other proteins that lack a natural puriﬁcation tag the application of a
His fusion tag is a simple and convenient puriﬁcation technique.
During this study, a number of feed stream factors were taken
into account that could affect protein yield or quality. Cell damage
plays an important role in the characteristics of feed streams
(Anspach et al., 1999; Salte et al., 2006) and has been shown to vary
widely across bioprocess operations (Hogwood et al., 2013; Kim
et al., 2013). We focused speciﬁcally on proteolytic activity and
hDNA contamination rather than host cell protein (HCP) content as
this is not directly linked to product degradation (Cordoba et al.,
2005). By contrast, proteases directly affect product stability and
afﬁnity tag cleavage (Gao et al., 2011). Contamination with hDNA
signiﬁcantly affects feed viscosity (Balasundaram et al., 2009), and
therefore, column pressure drop as well as needing tomeet stringent
regulatory standards in ﬁnal preparations (Nissom, 2007). In our
Figure 6. Cell survival and column flow characteristics of feed stream under optimized buffer conditions. A: CHO cell survival in buffered media with increasing NaCL
concentration over 60 min.B: Protease activity in unclarified feed stream andmaximum cell lyses samples after column flow bufferedwith 500mMNaCl, 20mM imidazole, and pH 8.5.
C: Host cell DNA in pre-column, flow through, and wash samples. D: PSD of feed stream from column buffered with 500mM NaCl, 20mM imidazole, and pH 8.5.
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Figure 7. Comparison of crude and processed feed applied to a RFC system packed with large diameter resin. A: Fed-batch shake flask growth of CHO cells expressing
His-tagged CEA. B: Viable cells/mL before and after passage through column. C: Protease activity in crude and processed feed streams. D: Percentage recovery of His-tagged CEA
from crude and processed feed streams.
Figure 8. Primary capture of His-tagged CEA from 3 L fed-batch bioreactor fermentation.A: Fed-batch fermentation of CHO in SUT bioreactor.B: Time course of CEA expression in
the bioreactor. C: Anti-CEAWestern blot of column eluate. D: Anti-HisWestern blot of column eluate. All elutions and positive control were diluted to 1mg/mL prior to western blotting.
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process, cell damage was predicted to occur during column passage,
especially as the cells traversed the relatively high shear regions of
the frit. Our results showed a loss of viability of between 2% and 4%
and no signiﬁcant difference between particle size distribution,
protease activity, or hDNA content in pre and post column samples.
By comparison, previous results of direct capture using expanded
bed adsorption (EBA) from hybridoma cells showed an increase in
hDNA contamination of up to 54% (Feuser et al., 1999).
The benchmark for primary protein recovery is currently axial
packed-bed chromatography; our results demonstrated that
percentage recovery of CEA was 17.9% greater in an axial
packed-bed column (89.16%) compared to capture from unclariﬁed
feed using the large diameter resin in radial ﬂow format (71.6%). In
industrial processes, His-tag recovery can be as high as 90%
(Saraswat et al., 2013). In this study, three buffer factors (pH,
imidazole, and NaCl concentration) were optimized for product
capture, however, a broader optimization of process factors (bead
diameter, bed height, load mass, ﬂow rate, cell density, temperature
etc.) would be expected to improve yield.
Our process utilized IDA chelating agarose beads of between
300mm and 500mm in diameter forming a packed resin charged
with nickel. However, a range of resins are available differing in
construction, functional groups, bead size, and packing density
(Bornhorst and Falke, 2000; Hochuli et al., 1987; Saraswat et al.,
2013; Warren and Bettadapura, 2005). These variables are expected
to have a signiﬁcant impact on performance and feed stream
characteristics, for example, bead diameter will directly affect
antiparticle porosity affecting cell travel through the column, ﬂuid
dynamics, and the shear rate experienced by the cells thus affecting
protein yield.
The improvement in process efﬁciency yielded from using an
integrated capture step would result in a reduction in COG/g and
has been shown previously with capture techniques from
unclariﬁed feeds (Sch€ugerl and Hubbuch, 2005). EBA, a format
with similar process advantages to large-bead resins, has been
compared with standard bioprocess techniques resulting in reduced
COG/g and simpliﬁed recovery in microbial and mammalian cell
downstream processing (Chhatre et al., 2006; Tolner et al., 2013;
Willoughby et al., 2004). Similar efﬁciency gains from the removal
of clariﬁcation steps could be expected with large bead
diameter resins. Uptake of novel techniques can be affected by
concerns over regulatory compliance however the combination of
RFC and EBA has been applied to unclariﬁed microbial fermen-
tation broths using His-tagged proteins previously in cGMP-
compliant processes (Tolner et al., 2013), showing that adoption of
similar approaches does not necessarily introduce regulatory
hurdles.
Conclusions
In conclusion, primary recovery of recombinant proteins from
unclariﬁed media is an attractive processing technique with the
potential to signiﬁcantly improve process efﬁciency. This study
demonstrates primary capture of heavily glycosylated, His-tagged
CEAusing large bead radial ﬂow Ni-IMAC chromatography without
detrimental affects on cell viability. Our approach could be applied
to the recovery of many different proteins from mammalian feed
streams using other modes of chromatographic interactions such as
afﬁnity and ion exchange chromatography.
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